AHS 2021 consensus on integrating new migraine therapies into clinical practice: Isn't our goal choice of best therapy regardless of cost?

Headache. 2022 Jan;62(1):109-110. doi: 10.1111/head.14232. Epub 2021 Nov 28.

Authors

James A Charles¹, Ira M Turner²

Affiliations

¹ Holy Name Medical Center, Teaneck, New Jersey, USA.
² PC - Headache, Island Neurological Associates, Plainview, New York, USA.

PMID: 34841535
DOI: 10.1111/head.14232

No abstract available

Keywords: abortives; choice of therapy; migraine; preventives.

Publication types

Letter

MeSH terms

Antibodies, Monoclonal / economics
Antibodies, Monoclonal / therapeutic use*
Calcitonin Gene-Related Peptide / immunology*
Calcitonin Gene-Related Peptide Receptor Antagonists / economics
Calcitonin Gene-Related Peptide Receptor Antagonists / therapeutic use*
Consensus*
Drug Prescriptions* / economics
Drug Prescriptions* / standards
Humans
Migraine Disorders* / drug therapy
Migraine Disorders* / economics
Migraine Disorders* / prevention & control
Societies, Medical / standards

Substances

Antibodies, Monoclonal
Calcitonin Gene-Related Peptide Receptor Antagonists
Calcitonin Gene-Related Peptide